<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003770.pub3" GROUP_ID="COLOCA" ID="761900010409493503" MERGED_FROM="" MODIFIED="2009-07-31 13:21:52 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old title: Hepatic Artery Adjuvant Chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver.&lt;/p&gt;&lt;p&gt;This version copy edited June 20 2006&lt;/p&gt;" NOTES_MODIFIED="2009-07-31 12:52:44 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="029" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-07-31 12:52:44 +0200" MODIFIED_BY="[Empty name]">
<TITLE>Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver</TITLE>
<CONTACT>
<PERSON ID="12864" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Richard</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Nelson</LAST_NAME>
<SUFFIX>M.D.</SUFFIX>
<POSITION/>
<EMAIL_1>altohorn@btinternet.com</EMAIL_1>
<EMAIL_2>Rick.Nelson@sth.nhs.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>07717 803 032</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>Northern General Hospital</ORGANISATION>
<ADDRESS_1>Herries Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sheffield</CITY>
<ZIP>S5 7AU</ZIP>
<REGION>Yorkshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 0114 271 5437</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 0114 226 6986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-07-31 12:44:01 +0200" MODIFIED_BY="Henning Keinke Andersen">
<PERSON ID="12864" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Richard</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Nelson</LAST_NAME>
<SUFFIX>M.D.</SUFFIX>
<POSITION/>
<EMAIL_1>altohorn@btinternet.com</EMAIL_1>
<EMAIL_2>Rick.Nelson@sth.nhs.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>07717 803 032</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>Northern General Hospital</ORGANISATION>
<ADDRESS_1>Herries Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sheffield</CITY>
<ZIP>S5 7AU</ZIP>
<REGION>Yorkshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 0114 271 5437</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 0114 226 6986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16982" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Sally</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Freels</LAST_NAME>
<SUFFIX>Ph.D.</SUFFIX>
<POSITION/>
<EMAIL_1>sallyf@uic.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology/Biometry</DEPARTMENT>
<ORGANISATION>University of Illinois School of Public Health</ORGANISATION>
<ADDRESS_1>953 SPHPI m/c 923</ADDRESS_1>
<ADDRESS_2>1603 West Taylor</ADDRESS_2>
<CITY>Chicago</CITY>
<ZIP>60612</ZIP>
<REGION>Illinois</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 312 996 4763</PHONE_1>
<PHONE_2/>
<FAX_1>1 312 996 0064</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-07-31 12:45:58 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="7" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="9" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2009-07-31 12:52:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This review is updated through December 2008. No new eligible studies have been published since the original review, so results and conclusions remain the same.&lt;/p&gt;" NOTES_MODIFIED="2009-07-31 12:52:44 +0200" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-31 12:45:51 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Searches revealed no new trials</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="31" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-07-28 19:01:22 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Chemotherapy delivered via the hepatic artery following surgical resection of liver metastases arising from colorectal cancer does not improve survival.</TITLE>
<SUMMARY_BODY>
<P>Patients who die of colorectal cancer usually die from, or at least with, liver metastases. On the other hand, isolated liver metastases can, on occasion, be resected with a chance of cure, if metastatic disease is not present elsewhere. After liver resection is performed for colorectal cancer metastases, the most common site of treatment failure is in the remaining liver. For that reason it has been proposed that chemotherapy be given in the hepatic artery after surgery to treat microscopic disease in the remaining liver. <BR/>This systematic review assesses the randomised trials that have addressed the effective ness of this additional chemotherapy. Seven studies have been published in this field, and the combined analysis shows that survival is not improved by hepatic artery chemotherapy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-28 19:00:30 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Colorectal cancer metastatic to the liver, when technically feasible, is resected with a moderate chance of cure. The most common site of failure after resection is within the remaining liver. With this pattern of clinical failure in mind and in order to enhance survival, chemotherapy has been delivered directly to the liver post resection via the hepatic artery. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effect of post hepatic resection hepatic artery chemotherapy on overall survival. Secondary objectives include adverse events related to the chemotherapy, the risk of intra-hepatic tumour recurrence and tumour free survival.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-28 19:00:30 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trials were sought in MEDLINE; the Cochrane Central Register of Controlled Trials; the Cochrane Hepato-Biliary Group Controlled Trials Register; and through contact of trial authors and reference lists using key words: Colorectal, cancer, hepatic metastases, hepatic artery, chemotherapy.<BR/>Searches were performed in December, 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Trials in which patients having resection of colorectal cancer metastatic to the liver were randomised either to hepatic artery chemotherapy or any alternative treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Survival data were obtained principally from abstraction from survival curves in published studies using the method of Parmar. A study specific log hazard ratio and then combined effect log hazard ratio were calculated, as well as a combined Kaplan-Meier survival probability curve.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seven randomised trials addressed this issue, encompassing 592 patients. No significant advantage was found in the meta-analysis for hepatic artery chemotherapy measuring overall survival and calculating survival based upon "intention to treat" (lnHR = 0.0848; favouring the control group, 95% confidence interval = -0.1189 to 0.2885, or a Hazard Ratio of 1.089, an 8.9% survival advantage for the control group, 95% CI of the HR = 0.887 - 1.334). Adverse events related to the hepatic artery therapy were common, including five therapy related deaths. Intra-hepatic recurrence was more frequent in the control group (97 patients versus 43 in the HAI group), though denominators are not reported, and additional outcomes could not be subjected to a combined analysis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Though recurrence in the remaining liver happened less in the hepatic artery chemotherapy group, overall survival was not improved, and even favoured the control group, though not significantly. This added intervention cannot be recommended at this time. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-07-28 19:01:22 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Hepatic resection and/or ablation of metastases to the liver of colorectal cancer are being done with increasing frequency and a moderate chance of cure (<LINK REF="REF-Iwatsuki-1999" TYPE="REFERENCE">Iwatsuki 1999</LINK>) in highly selected patients. No randomised studies have been performed to assess the relative effectiveness of surgical resection against any alternative therapy, including either cryo or radiofrequency ablation of metastatic disease. Since the most common site of failure after liver resection in many reports is in the remaining liver, i.e., the growth of microscopic disease in the liver not detected at the time of surgery (<LINK REF="REF-Bozzetti-1986" TYPE="REFERENCE">Bozzetti 1986</LINK>), chemotherapy has been administered via the hepatic artery after hepatic resection to focus adjuvant treatment on this most likely site of recurrence. Seven randomised controlled trials have been performed testing this hypothesis, the results of which have varied (<LINK REF="REF-Kemeny--1999" TYPE="REFERENCE">Kemeny 1999</LINK>; <LINK REF="STD-Kemeny-2002" TYPE="STUDY">Kemeny 2002</LINK>; <LINK REF="STD-Lorenz-1998" TYPE="STUDY">Lorenz 1998</LINK>; <LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>; <LINK REF="STD-Rudroff-1999" TYPE="STUDY">Rudroff 1999</LINK>; <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>; <LINK REF="STD-Wagman-1990" TYPE="STUDY">Wagman 1990</LINK>; ). We performed the first meta-analysis of reported randomised trials in order to assess the efficacy and morbidity of adjuvant chemotherapy delivered in the hepatic artery after hepatic resection of colorectal tumour metastases.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The principal objective of this review is to determine if delivery of chemotherapy via the hepatic artery after resection of cancer of the colon metastatic to the liver confers a survival advantage. Secondary objectives include the risk of recurrence of tumour within the remaining liver and assessment of adverse events related to this therapy. Tumour free survival and the effect of intra-hepatic chemotherapy on quality of life were also sought.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-07-28 19:01:00 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials in which patients having curative resection of liver metastases, either concurrently with colon resection or at a time distant from the colon resection, are allocated either to a hepatic artery chemotherapy group or a control group (which may or may not include systemic chemotherapy) and in which the patients were followed for a sufficient amount of time to assess survival.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Individuals with cancer of the colon or rectum with metastases to the liver that are candidates for liver resection, i.e., with no evidence of primary or metastatic cancer elsewhere, except for those who are having the primary carcinoma of the colorectum resected simultaneously with the liver resection.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The test group will have had placement of an hepatic artery catheter at the time of liver resection, but after randomizations, i.e., there are no studies in which an hepatic artery catheter was placed for the possible administration of a placebo with post-operative randomizations. The control groups were either treated by surgery alone or surgery followed by systemic chemotherapy. The inclusion of systemic chemotherapy in some control groups is a potential confounding variable in this review and results will be reported plus and minus those studies in sensitivity analyses.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Overall Survival probability and<BR/>Adverse events related to catheter placement or administration of the chemotherapy were the primary endpoints assessed</P>
<P>Intra-hepatic tumour recurrence,<BR/>Time to recurrence,<BR/>Extra-hepatic tumour recurrence, <BR/>Time to recurrence and <BR/>Disease specific survival were secondary endpoints sought in the reported studies </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-28 19:01:00 +0200" MODIFIED_BY="[Empty name]">
<P>MEDLINE search using key words: colorectal, cancer, liver, metastases, resection, chemotherapy, hepatic artery, randomised trial, in various combinations from 1966 to December, 2008.<BR/>The Cochrane Controlled Trials Register and EMBASE were searched with similar key words and the Cochrane Hepatobiliary Controlled Trial Register also was reviewed. None of the seven study authors were aware of any other published or ongoing studies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data were extracted from the studies using the above endpoints. Authors have been contacted in each of the above seven studies requesting updated crude data. Four immediately complied, one demanded first authorship of the review for only contributing his data, another had many questions and one has refused to respond. Fortunately the authors not contributing data have quite detailed survival curves in their published reports. </P>
<P>
<B>Meta-analysis of overall survival</B>: A method has been published for the extraction of summary data from survival curves for the purpose of doing meta-analyses in time to event survival studies (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). The principal endpoint, duration of survival, is assessed for each study using the log hazard ratio, a statistic that best combines time to event and censoring in survival studies (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). The meta-analysis is also done using this approach and a summary Kaplan-Meier Survival curve constructed (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). </P>
<P>
<B>Sensitivity analyses</B>: Several of the studies in this review enrolled only a small number of patients (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>; <LINK REF="STD-Rudroff-1999" TYPE="STUDY">Rudroff 1999</LINK>; <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>; <LINK REF="STD-Wagman-1990" TYPE="STUDY">Wagman 1990</LINK>). This meant that in many of the time intervals in which overall mortality was measured there were no events - no deaths. It is recommended that in such situations very small numbers be inserted into the data extraction tables (e.g.0.000001) to avoid division by a zero denominator. This effectively eliminated the smaller studies from consideration. It is further recommended and that concatenating intervals be avoided as a means of assuring that an event - a death - occurred at each measurement point (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). The effect of such concatenation of the time intervals in smaller studies was assessed, which required considerable widening of the intervals in the smaller studies, by comparing this maneuver to the recommended technique of small number insertion, and, in this review, adherence to annual measurement intervals. The top three rows of (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) use uniform yearly intervals for mortality determination in all studies. The last two rows vary the intervals for each study to assure that an event occurs in each interval. This was intended as a sensitivity analyses to assess the robustness of this statistical technique. <BR/>Further sensitivity analyses were performed to assess the effect of exclusion of studies with either quality concerns or confounding data on the summary log hazard ratio for overall survival. The rationale for these exclusions can be found under the Methodological Quality of included studies section. The analyses can be found in rows two and three in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<P>Heterogeneity was calculated using the general variance based method (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>) with and without (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>). Quantitation of heterogeneity was done using the I square method of (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-07-28 19:01:22 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-07-28 19:01:22 +0200" MODIFIED_BY="[Empty name]">
<P>Seven RCTs have been published from 1990 to December, 2008. These were all found in Medline, with no additional studies disclosed through other data bases or in communications with study authors.</P>
<P>These seven studies incorporated including 592 patients, 302 in the control group and 289 in the hepatic artery chemotherapy group, three from the United States, two from Germany, one from Greece and one from Japan. Details of type and duration of chemotherapy are presented in (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). All seven studies are included in this review. No non-randomised studies were used in the meta-analysis. Randomizations or allocation to study group occurred intra-operatively after determination that a curable hepatic resection was feasible in four studies (<LINK REF="STD-Kemeny-1999" TYPE="STUDY">Kemeny 1999</LINK>; <LINK REF="STD-Rudroff-1999" TYPE="STUDY">Rudroff 1999</LINK>; <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>; <LINK REF="STD-Wagman-1990" TYPE="STUDY">Wagman 1990</LINK>). Five studies used computerized tomography to assure that metastatic disease was not present outside the liver in the pre-operative period. The two studies that did not use this technique did not random ize patients until surgery and thus used operative exploration to rule out extra-hepatic metastases (<LINK REF="STD-Rudroff-1999" TYPE="STUDY">Rudroff 1999</LINK>, <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>). One study used a novel technique of randomization, with pre-operative randomization to an A or B therapy group, but the therapy allocation was determined by operative findings, i.e. there were three strata of therapy pairs depending upon whether the patient had (A) extra-hepatic metastases, (B) unresectable liver metastases or (C) resectable liver metastases (<LINK REF="STD-Wagman-1990" TYPE="STUDY">Wagman 1990</LINK>). This method accounts for the very small number of participants in the (C) portion of their study relevant to this review. In two other studies using pre-operative randomization (<LINK REF="STD-Kemeny-2002" TYPE="STUDY">Kemeny 2002</LINK>; <LINK REF="STD-Lorenz-1998" TYPE="STUDY">Lorenz 1998</LINK>), a number of patients were found during abdominal exploration to be ineligible for hepatic artery catheter chemotherapy, due in most cases to metastases found outside of the liver, or unresectable liver disease. The patients were fortunately followed for survival but not treated with hepatic artery chemotherapy. A number of other participants had difficulties with catheter insertion or function that resulted in no catheter insertion in some cases, misdirected catheter insertion in others and in such cases no chemotherapy was administered. Those found to have tumour at the margin of hepatic resection, suggesting non-curative resection and of course those that died in the early post-operative period also never received chemotherapy. Only 234 members of the hepatic artery chemotherapy group (81%) got any chemotherapy in the post-operative period. One study reported that only 26% of its participants completed all recommended cycles of hepatic artery chemotherapy due to deaths and other adverse events (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) such as appearance of recurrent metastatic disease, toxicity of the chemotherapy, catheter malfunction or sepsis (<LINK REF="REF-Kemeny--1999" TYPE="REFERENCE">Kemeny 1999</LINK>). Many of these problems were encountered in other included studies, and of course most of them could not occur in the control groups.</P>
<P>The therapy delivered through the hepatic artery varied considerably from study to study both in composition and duration (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). They were all similar in several important respects; being all uracil based and all delivered in high concentrations via the hepatic artery. The studies to that degree are therefore all comparable and suitable for meta-analysis.</P>
<P>Intra-hepatic tumour recurrence,</P>
<P>Time to recurrence,</P>
<P>Extra-hepatic tumour recurrence,</P>
<P>Time to recurrence and</P>
<P>Disease specific survival are desirable outcomes to assess but are not reported in the published RCTs in a standard fashion that allowed quantitative compilation of the data. No report presents data that allow a cost comparison or quality of life assessment of various therapies and so these endpoints will not yet be considered, especially in light of the results of the meta-analysis.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Methodological quality needs to be considered in this review, though difficult to assess. Technique and timing of randomization is one area where this can be considered. For instance, hepatic resection is not recommended if metastatic disease is found outside the liver. In most studies randomization was delayed until abdominal exploration was complete in the operating room to assure patient eligibility. When randomizations occurred before surgery and yet 100% of the patients had a successful resection, one might be concerned about quality (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>). Only two RCTs specified the technique of randomizations, the drawing of cards (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>; <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>). Blinding of neither surgeon nor patient was done in any of these studies. No mention of outcome assessment by blinded investigators was made in any publication. No hepatic artery catheters were inserted for the administration of placebo.</P>
<P>
<B>Sensitivity analyses</B> were conducted to assess several issues related to quality, potential confounding therapy and validity of this statistical method. <BR/>The <B>first relates to quality</B> and the discussion of randomizations in the previous paragraph, operative findings and the delivery of therapy. Pre-operative imaging for the detection of metastatic disease is often imprecise and underestimates the actual disease burden. For that reason many patients in whom resection of hepatic metastases from colorectal cancer is planned do not get the procedure because additional metastases are discovered during surgery that makes the disease incurable by any operation. It is also not uncommon for catheter insertion in patients intended to get hepatic artery chemotherapy to be difficult and even unsuccessful. For that reason 4 of 7 studies randomised patients only during surgery - creating at least a little problem with informed consent - in order to appropriately assess their eligibility for the study (<LINK REF="REF-Kemeny--1999" TYPE="REFERENCE">Kemeny 1999</LINK>; <LINK REF="STD-Rudroff-1999" TYPE="STUDY">Rudroff 1999</LINK>; <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>; <LINK REF="STD-Wagman-1990" TYPE="STUDY">Wagman 1990</LINK>). Two additional studies randomised pre-operatively but then during surgery found many randomised patients were ineligible for the therapy. "As treated" and "Intention to Treat" became, in this situation, very disparate numbers (<LINK REF="STD-Kemeny-2002" TYPE="STUDY">Kemeny 2002</LINK>; <LINK REF="STD-Lorenz-1998" TYPE="STUDY">Lorenz 1998</LINK>). Only one study randomised pre-operatively and yet treated all patients as randomised, suggesting a problem with quality of assessment or allocation (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>). When tables describe analysis of 6 studies only, it means with the exclusion of this study. </P>
<P>
<B>The second, relating to confounders</B>: there are two studies that treated all members of the control group with systemic chemotherapy, feeling that this was the "best standard care", though no data exist from randomised studies to support this plan. When tables describe analyses of 4 studies only it is with the exclusion of the study above (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>) and the two studies using systemic chemotherapy in controls (<LINK REF="REF-Kemeny--1999" TYPE="REFERENCE">Kemeny 1999</LINK>; <LINK REF="STD-Tono-2000" TYPE="STUDY">Tono 2000</LINK>). The only study that showed a significantly improved survival delivered a massive range of chemotherapy for an unusually long period of time without reported adverse effect, which further separates it from other publications (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>). The same study had an unusual relationship of randomizations and surgical outcome that also suggested it was one to segregate in sensitivity analysis.</P>
<P>
<B>The third relates to the statistical technique</B>: The concantination of time intervals to insure that an event, a death, occurred in as many studies as possible in each measurement interval had a minor effect on the summary statistics (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>), when compared to the maintanence of uniform time itnervals and insertion of very samll event numbers as recommended by (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The log hazard ratio (lnHR) for <B>overall survival</B> all studies combined is greater than zero, and therefore the meta-analysis shows diminished all cause mortality risk for the control group compared to the hepatic artery chemotherapy (HAI) group. The sensitivity analyses further strengthen this finding, increasing the lnHR in all but one case, and in each case remaining greater than zero (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). That is, exclusion of studies from analysis that had concerns over quality or confounding increased the survival probability of the control group over the hepatic artery chemotherapy group. The range of survival benefit varies in these analyses from 4% to 27% in the control group. It is 8.9% in the full analysis. However, none of these analyses demonstrate a statistically significant difference between the control group and the HAI group. The 95% confidence intervals in each case cross zero. </P>
<P>The summary survival probability curve is shown in (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Once again in the <B>overall survival curve </B>no overall survival advantage is shown for hepatic artery chemotherapy. The reliability of the comparison of the survival curves diminishes to the right of the curve as the number of patients being assessed declines markedly and the standard error increases from 0.03 in year two to 0.23 in year seven, reflecting the decline in number of patients at risk in each time interval from 592 at year 0 to 30 at year 7.</P>
<P>On the other hand, 43 patients developed <B>recurrence within the remaining liver</B> of colorectal cancer in the HAI group and 97 patients developed recurrence in the control group (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). A rate for this finding, and thus test for statistical significance, cannot be calculated from the data presented because of uncertainty about the denominators, as the time of recurrence varies or is not in some cases specified. </P>
<P>Appropriate analyses (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) demonstrated that, measuring <B>overall survival in individual studies</B>, only one showed a statistically significant result, favouring hepatic artery chemotherapy (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>). Many of the studies claimed in publication that their results were statistically significant, using inappropriate techniques of analysis; only one (<LINK REF="STD-Lorenz-1998" TYPE="STUDY">Lorenz 1998</LINK>) used hazard ratio in calculating effect. Significance was unearthed by individual study authors choosing arbitrary points in follow up, by analysing patients "as treated" or perhaps not accounting for right censoring of subjects, an integral part of time to event assessments.</P>
<P>Other endpoints are more problematic. In the published studies sufficient data are not presented to perform similar analyses for tumour free survival and hepatic recurrence free survival. Nor are adverse events routinely described. As stated above, attempts to obtain individual patient data have only been partially successful, and only from the smallest studies.</P>
<P>
<B>Adverse events</B> in the overall intervention group were common, including toxicity of the chemotherapy that limited the number of cycles subjects could tolerate, as mentioned above. In addition catheter sepsis, venous thrombosis and catheter dislodgment were also reported. Five deaths were directly attributed to the therapy.</P>
<P>
<B>Disease free survival</B> was often reported, but in a manner that usually made time to event impossible to calculate, much less use in a combined analysis.</P>
<P>
<B>Quality of Life</B> was not discussed nor data presented in any study.</P>
<P>
<B>Heterogeneity</B> was calculated including all studies (chi square = 8.918; six degrees of freedom, p &gt; 0.10. When one study was excluded (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>), the calculation of heterogeneity was chi square = 3.75; five degrees of freedom, p &gt; 0.7. In both situations statistically significant heterogeneity was not detected. The I square for all studies was 33% (33% of the observed variation across studies due to heterogeneity), whereas for the studies excluding (<LINK REF="STD-Lygidakis-1995" TYPE="STUDY">Lygidakis 1995</LINK>), the I square was 0% (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>
<B>Captions for Tables<BR/>
</B>
<BR/>
<B>Table 01<BR/>
</B>HAI Hepatic Artery Chemotherapy Group<BR/>5FU 5 Fluorouracil<BR/>FUdR Fluorouracil deoxyribose<BR/>Mit. C Mitomycin C</P>
<P>
<B>Table 02<BR/>
</B>A lnHR &gt;0 favours the Control Group<BR/> &lt;0 favours Hepatic Artery Chemotherapy<BR/>IO Intra-operative randomizations<BR/>PO Pre-operative randomizations</P>
<P>All Analyses except Lygidakis are not statistically significant</P>
<P>
<B>Table 03<BR/>
</B>lnHR &gt;0 favours the control group for overall survival<BR/>NS Not statistically significant</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This systematic review provides little support for the addition of hepatic artery chemotherapy after hepatic resection of metastatic colorectal cancer. Though hepatic recurrence was seen less, the significance of this observation could not be properly assessed in the published studies because of the methods of data presentation. Overall survival was not enhanced, and in fact was 9% worse. The survival advantage in the control group did not reach statistical significance, so a potential survival advantage of the intervention . The sensitivity analyses further strengthened the conclusion, in no case demonstrating an advantage to the intervention group, ranging from 4% to 27% survival advantage in controls in the various analyses. The hepatic artery chemotherapy was not without risk as well, frequently associated with morbidity and occasionally therapy related death in 1.7% of those randomised to intra-hepatic artery chemotherapy.</P>
<P>In several individual publications calculation of statistical significance was made based upon patients "as treated" rather than allocation according to the original randomizations, an error that inevitably selected out from analysis those hepatic artery chemotherapy patients who were destined to have the worst outcome. The sensitivity analyses were undertaken to segregate studies of questionable quality, those in which significant confounding therapies may have been applied, i.e., systemic chemotherapy in the control group, and to assess the variability in the method of log hazard ratio calculation when time intervals were varied. In addition, when data were presented in a manner that allowed additional approaches, log hazard ratios were calculated by alternate methods to assess the robustness of the method used most frequently, abstraction from survival curves. In each of these cases there was little variation in the overall results, (data not shown). </P>
<P>This review covers 592 patients. A larger population might have disclosed a benefit to HAI, since the confidence intervals cross zero (or 1.0 for the hazard ratio). But this is very unlikely since the trend is clearly in favour of the control group for overall survival, and the statistical power of this sample size to detect as little as a 5% difference in overall survival is greater than 0.8 ( <I>http://calculators.stat.ucla.edu/powercalc/</I> ) . Another lingering issue is how the control group should be treated. Ethical considerations mandate best standard care, and probably eliminate the possibility of a true placebo controlled trial in which hepatic artery catheters are inserted for sham therapy. Systemic chemotherapy is where opinions differed in the reported trials, though the benefit of systemic chemotherapy in this setting has not been established. Until that time, an unblinded no treatment control after hepatic resection is probably the best comparison group.</P>
<P>In order to construct a survival curve of the combined studies, a correction was necessary in the publication by Parmar (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). In equation #23 the second term on the right should be an estimate of the conditional probability of surviving <BR/>from <B>
<I>t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>
<SUP>-1</SUP>
</I>
</B>
<I>
<SUP>
<BR/>
</SUP>
</I> to <B> t</B>
<B>
<SUB>e</SUB>
</B>
<SUB> ,</SUB> or <B>
<I>S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>)/S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>
<SUP>-1</SUP>
</I>
</B>
<B>
<I>)</I>
</B>
<I> .<BR/>
</I> <BR/>A reasonable estimate of this would be the weighted sum of conditional probabilities from each study, or <BR/> k<BR/> <B>&#931;</B> [<B>
<I>S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>)/S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>
<SUP>-1</SUP>
</I>
</B>
<B>
<I>)</I>
</B> ] x <B>
<I>w</I>
</B>
<B>
<I>
<SUB>ci</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>)</I>
</B>
<BR/> i=1<BR/>Thus the entire correct equation should be<BR/> k<BR/>
<B>
<I> S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>) = S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>
<SUP>-1</SUP>
</I>
</B>
<B>
<I>) x </I>
</B>
<B>&#931;</B>
<B> </B>
<B>
<I> [S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>)/S</I>
</B>
<B>
<I>
<SUB>c</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>
<SUP>-1</SUP>
</I>
</B>
<B>
<I>)] x w</I>
</B>
<B>
<I>
<SUB>ci</SUB>
</I>
</B>
<B>
<I>(t</I>
</B>
<B>
<I>
<SUB>e</SUB>
</I>
</B>
<B>
<I>)</I>
</B> <BR/> i=1</P>
<P>where t<SUB>e</SUB> = the last measured time interval<BR/> S<SUB>c</SUB> = the survival probability at time interval t in the control group<BR/> w<SUB>ci</SUB> = weight assigned to each study in the control group<BR/> i = individual study summed, from i=1 to i=kth study.<BR/> <BR/>If this correction is not used, there is a precipitous fall in all survivals, much steeper than in any of the individual studies (<LINK REF="REF-Freels-2004" TYPE="REFERENCE">Freels 2004</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Without evidence of improved survival hepatic artery infusion chemotherapy after resection of colorectal cancer metastatic to the liver cannot be recommended.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This intervention seemed to be effective in diminishing hepatic recurrence. More precise definition of failure patterns may disclose additional therapy that could improve survival. Also liver metastases are now frequently being treated not by resection but ablation. This has diminished the morbidity associated with hepatic resection, and expanded the number of patients whose liver metastases can be treated. Randomised trials are needed to assess the relative effectiveness of liver resection compared to many alternative therapies in patients with surgically resectable metastases from colorectal cancer and no signs of metastatic disease elsewhere. A study in which the control group gets either no treatment or systemic chemotherapy or regional chemotherapy may never be done because historic comparisons have shown survival from liver resection in selected patients and not with these other therapies (<LINK REF="REF-Iwatsuki-1999" TYPE="REFERENCE">Iwatsuki 1999</LINK>). A direct comparison of resection to ablation is much more feasible. The development of adjuvant therapy added to ablation that might increase survival may also be the next priority.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-05 10:02:50 +0200" MODIFIED_BY="[Empty name]">
<P>None</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Dr. Freels provided statistical expertise in the meta-analysis, including correction of a key equation used for combined survival curve construction.<BR/>Dr. Nelson conceived the project, searched the field, abstracted the data, performed the statistical analyses, wrote the text of the review and is primarily responsible for its conclusions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>The old title for the protocol 'Adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver', was changed to the present after suggestion from one of the peer reviewers. <BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemeny-1999" NAME="Kemeny 1999" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny N, Huang Y, Cohen AM, Shi W, et al</AU>
<TI>Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.</TI>
<SO>N Eng J Med</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>27</NO>
<PG>2039-2048</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny N, Huang Y, Cohen AM, Shi W, et al</AU>
<TI>Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.</TI>
<SO>N Eng J Med</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>27</NO>
<PG>2039-2048</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemeny-2002" NAME="Kemeny 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny MM, Adak S, Gray B, MacDonald JS, et al</AU>
<TI>Combined Modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study</TI>
<SO>J. Clin. Oncol.</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>1499-1505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorenz-1998" NAME="Lorenz 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorenz M, Mueller HH, Schramm H, Gassel HJ, et al</AU>
<TI>Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for live metastases of colorectal cancer</TI>
<SO>Ann Surg</SO>
<YR>1998</YR>
<VL>228</VL>
<NO>6</NO>
<PG>756-762</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lygidakis-1995" NAME="Lygidakis 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lygidakis NJ, Ziras N, Parissis J</AU>
<TI>Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem.</TI>
<SO>Hepatogastroenterol</SO>
<YR>1995</YR>
<VL>42</VL>
<PG>155-161</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudroff-1999" NAME="Rudroff 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudroff C, Altendorgf-Hoffmann, Stangl R, Scheele J</AU>
<TI>Prospective randomized trial on adjuvant hepatic artery infusion chemotherapy after R0 resection of colorectal liver metastases</TI>
<SO>Langenbeck's Arch Surg</SO>
<YR>1999</YR>
<VL>384</VL>
<PG>243-249</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tono-2000" NAME="Tono 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tono T, Hasuike Y, Ohzato H, Takasuka Y, Kikkawa N.</AU>
<TI>Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases.</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>7</NO>
<PG>1549-1556</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagman-1990" NAME="Wagman 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagman LD, Kemeny MM, Leong L, Terz JJ, et al</AU>
<TI>A prosepctive randomized evaluation of the treatment of colorectal cancer metastatic to the liver.</TI>
<SO>J Clin Oncol</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>11</NO>
<PG>1885-1893</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bozzetti-1986" NAME="Bozzetti 1986" TYPE="JOURNAL_ARTICLE">
<AU>Bozzetti F, Bignami P, Morabito A, Doci R, Gennari L.</AU>
<TI>Patterns of failure following surgical resection of colorectal cancer liver metastases</TI>
<SO>Ann Surg</SO>
<YR>1987</YR>
<VL>205</VL>
<NO>3</NO>
<PG>264-269</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freels-2004" NAME="Freels 2004" TYPE="CORRESPONDENCE">
<AU>Freels S</AU>
<SO>Statistics in Medicine</SO>
<YR>in press</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>Brit Med J</SO>
<YR>6/9/2003</YR>
<VL>327</VL>
<PG>557-560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iwatsuki-1999" NAME="Iwatsuki 1999" TYPE="JOURNAL_ARTICLE">
<AU>Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE.</AU>
<TI>Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.</TI>
<SO>J Amer. Col. Surg.</SO>
<YR>1999</YR>
<VL>189</VL>
<NO>3</NO>
<PG>291-299</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemeny--1999" NAME="Kemeny  1999" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny N, Huang Y, Cohen AM, Shi W, et al</AU>
<TI>Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.</TI>
<SO>N Eng J Med</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>27</NO>
<PG>2039-2048</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L.</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Stat in Med</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-2834</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" NAME="Petitti 1994" TYPE="BOOK">
<AU>Petitti, Diana, B.</AU>
<TI>Meta-analysis, decision analysis and cost effectiveness analysis</TI>
<SO>Meta-analysis, decision analysis and cost effectiveness analysis</SO>
<YR>1994</YR>
<EN>first</EN>
<PB>Oxford University Press</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="isbn  0-19-507334-7"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-28 19:08:41 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-28 19:08:41 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Kemeny-1999">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal cancer (CRC) metastatic to the liver eligible for resection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR (liver resection) + hepatic artery chemotherapy vs no hepatic artery therapy. Both groups received systemic chemotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival (OS),<BR/>Disease free survival (DFS), <BR/>Hepatic resection FS, <BR/>toxicity, <BR/>surgical &amp; catheter related adverse events,</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Actuarial analysis supported the use of hepatic artery injection of adjuvant chemotherapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kemeny-2002">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal cancer (CRC) metastatic to the liver eligible for resection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR (liver resection) + hepatic artery chemotherapy (HAI)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival (OS),<BR/>Disease free survival (DFS), <BR/>Hepatic resection FS, <BR/>toxicity,</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Hepatic resection significant improved by HAI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lorenz-1998">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal Cancer (CRC) metastastatic to the liver, eligible for liver resection (LR) based upon pre-operative imaging</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR + hepatic artery chemotherapy (HAI) versus LR alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall Survival (OS)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study terminated due to diminished probability of determined benefit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lygidakis-1995">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal cancer (CRC) metastatic to the liver eligible for resection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR (liver resection) + hepatic artery chemotherapy (HAI)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival (OS),<BR/>Disease free survival (DFS), <BR/>Hepatic resection FS, <BR/>toxicity,</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>marked benefit in Hepatic resection with multi-modality HAI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rudroff-1999">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal cancer (CRC) metastatic to the liver eligible for resection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR (liver resection) + hepatic artery chemotherapy (HAI)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival (OS),<BR/>Disease free survival (DFS), <BR/>Hepatic resection FS, <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HAI not warranted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tono-2000">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal cancer (CRC) metastatic to the liver eligible for resection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR (liver resection) + hepatic artery chemotherapy (HAI)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival (OS),<BR/>Disease free survival (DFS), <BR/>Hepatic resection FS, <BR/>toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HAI provides significant disease free survival benefit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wagman-1990">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Colorectal cancer (CRC) metastatic to the liver eligible for resection (LR)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LR + hepatic artery chemotherapy (HAI)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Time to Failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Extended Disease free survival (DFS) with HAI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-07-28 19:08:41 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-28 19:08:07 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-07-28 19:08:16 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 19:08:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-07-28 19:08:30 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 19:08:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 19:08:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-28 19:08:41 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-28 19:08:41 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-07-28 19:08:07 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kemeny-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lorenz-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lygidakis-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rudroff-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tono-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wagman-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Characteristics of Studies</TITLE>
<TABLE COLS="8" ROWS="9">
<TR>
<TH>
<P>STUDY</P>
</TH>
<TH>
<P>Yes or No</P>
</TH>
<TH>
<P>Agents</P>
</TH>
<TH>
<P>Months</P>
</TH>
<TH>
<P>Yes or No</P>
</TH>
<TH>
<P>Number</P>
</TH>
<TH>
<P>Liver Recurrence</P>
</TH>
<TH>
<P>Liver Recurrence</P>
</TH>
</TR>
<TR>
<TD>
<P>Authors</P>
</TD>
<TD>
<P>Systemic Chemotherapy in Controls?</P>
</TD>
<TD>
<P>HAI Chemo</P>
</TD>
<TD>
<P>Duration HAI Chemo</P>
</TD>
<TD>
<P>Post Randomization Exclusions</P>
</TD>
<TD>
<P>Operative Mortality</P>
</TD>
<TD>
<P>HAI</P>
</TD>
<TD>
<P>Control</P>
</TD>
</TR>
<TR>
<TD>
<P>Wagman</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>FUdR</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Lygidakis</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>5FU, Mit. C, Folinic Acid, gamma interferon, Carboplastin, Farmorubicin</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Lorenz</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>5FU, Folinic Acid</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>Rudroff</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>5FU, Mit. C</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>NKemeny</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Floxuridine</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>MKemeny</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>FUdR + Syst. 5FU</P>
</TD>
<TD>
<P>4 HAI; <BR/>8 Systemic</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>Tono</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>5FU</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Individual Study Analyses of Overall Survival</TITLE>
<TABLE COLS="10" ROWS="9">
<TR>
<TH>
<P>STUDY</P>
</TH>
<TH>
<P>Minimum - Months</P>
</TH>
<TH>
<P>Maximum - Months</P>
</TH>
<TH>
<P>Randomization</P>
</TH>
<TH>
<P>Log Hazard Ratio</P>
</TH>
<TH>
<P>Variance of lnHR</P>
</TH>
<TH>
<P>Standard Error lnHR</P>
</TH>
<TH>
<P>95% confidence inter</P>
</TH>
<TH>
<P>Number Subjects</P>
</TH>
<TH>
<P>HAI as treated</P>
</TH>
</TR>
<TR>
<TD>
<P>Authors</P>
</TD>
<TD>
<P>Follow-up</P>
</TD>
<TD>
<P>Follow-up</P>
</TD>
<TD>
<P>When How</P>
</TD>
<TD>
<P>lnHR</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>HAI Control</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wagman</P>
</TD>
<TD>
<P>44.3</P>
</TD>
<TD>
<P>81.6</P>
</TD>
<TD>
<P>IO NS</P>
</TD>
<TD>
<P>-0.6293</P>
</TD>
<TD>
<P>1.0989</P>
</TD>
<TD>
<P>1.0483</P>
</TD>
<TD>
<P>+/- 2.0547</P>
</TD>
<TD>
<P>6 5</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Lygidakis</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>PO Cards</P>
</TD>
<TD>
<P>-0.8059</P>
</TD>
<TD>
<P>0.1418</P>
</TD>
<TD>
<P>0.3766</P>
</TD>
<TD>
<P>+/- 0.7383</P>
</TD>
<TD>
<P>20 20</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
<TR>
<TD>
<P>Tono</P>
</TD>
<TD>
<P>49.5</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>IO Cards</P>
</TD>
<TD>
<P>-0.8004</P>
</TD>
<TD>
<P>1.0340</P>
</TD>
<TD>
<P>1.0169</P>
</TD>
<TD>
<P>+/- 1.9931</P>
</TD>
<TD>
<P>9 10</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>NKemeny</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>IO NS</P>
</TD>
<TD>
<P>-0.0510</P>
</TD>
<TD>
<P>0.0486</P>
</TD>
<TD>
<P>0.2205</P>
</TD>
<TD>
<P>+/- 0.4322</P>
</TD>
<TD>
<P>74 82</P>
</TD>
<TD>
<P>68</P>
</TD>
</TR>
<TR>
<TD>
<P>MKemeny</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>PO NS</P>
</TD>
<TD>
<P>0.3382</P>
</TD>
<TD>
<P>0.0476</P>
</TD>
<TD>
<P>0.2182</P>
</TD>
<TD>
<P>+/- 0.4277</P>
</TD>
<TD>
<P>53 56</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>Rudroff</P>
</TD>
<TD>
<P>145</P>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>IO NS</P>
</TD>
<TD>
<P>0.2885</P>
</TD>
<TD>
<P>0.1614</P>
</TD>
<TD>
<P>0.4017</P>
</TD>
<TD>
<P>+/- 0.7873</P>
</TD>
<TD>
<P>14 16</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>Lorenz</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>PO NS</P>
</TD>
<TD>
<P>0.1988</P>
</TD>
<TD>
<P>0.0279</P>
</TD>
<TD>
<P>0.1670</P>
</TD>
<TD>
<P>+/- 0.3274</P>
</TD>
<TD>
<P>113 113</P>
</TD>
<TD>
<P>84</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Summary &amp; Sensitivity Analyses</TITLE>
<TABLE COLS="6" ROWS="6">
<TR>
<TH>
<P>Included Studies</P>
</TH>
<TH>
<P>Summary lnHR</P>
</TH>
<TH>
<P>Variance lnHR</P>
</TH>
<TH>
<P>Standard Error</P>
</TH>
<TH>
<P>95% Conf. Int.</P>
</TH>
<TH>
<P>Significance</P>
</TH>
</TR>
<TR>
<TD>
<P>All Studies</P>
</TD>
<TD>
<P>0.0848</P>
</TD>
<TD>
<P>0.0108</P>
</TD>
<TD>
<P>0.1039</P>
</TD>
<TD>
<P>+/- 0.2037</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>6 Studies, Excluding Lygidakis</P>
</TD>
<TD>
<P>0.1584</P>
</TD>
<TD>
<P>0.0117</P>
</TD>
<TD>
<P>0.1082</P>
</TD>
<TD>
<P>+/- 0.2037</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>4 Studies, Excluding Lygidakis, NKemeny, Tono</P>
</TD>
<TD>
<P>0.2405</P>
</TD>
<TD>
<P>0.0158</P>
</TD>
<TD>
<P>0.1257</P>
</TD>
<TD>
<P>+/- 0.2463</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Concantinating Intervals: 7 Studies, to avoid "no event" intervals</P>
</TD>
<TD>
<P>0.0404</P>
</TD>
<TD>
<P>0.0102</P>
</TD>
<TD>
<P>0.1010</P>
</TD>
<TD>
<P>+/- 0.1979</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Concantinating Intervals: 6 Studies, Excluding Lygidakis; to avoid "no event" intervals</P>
</TD>
<TD>
<P>0.1287</P>
</TD>
<TD>
<P>0.0110</P>
</TD>
<TD>
<P>0.1049</P>
</TD>
<TD>
<P>+/- 0.2056</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Overall Survival</NAME>
<IV_OUTCOME CHI2="9.266526452464472" CI_END="1.3358083899764532" CI_START="0.8887649307635138" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="1.0895960954549826" ESTIMABLE="YES" I2="35.25081883941232" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1257441668641805" LOG_CI_START="-0.0512130902917271" LOG_DATA="YES" LOG_EFFECT_SIZE="0.037265538286226745" NO="1" P_CHI2="0.15913442419037283" P_Q="1.0" P_Z="0.40908775841122236" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="289" TOTAL_2="302" WEIGHT="100.00000000000001" Z="0.8255000566735952">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Hepatic Artery Chemo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.463999477428166" CI_START="0.6168236844286619" EFFECT_SIZE="0.950278670532427" ESTIMABLE="YES" ESTIMATE="-0.051" LOG_CI_END="0.16554092170180992" LOG_CI_START="-0.20983895885594156" LOG_EFFECT_SIZE="-0.02214901857706582" ORDER="1" SE="0.2205" STUDY_ID="STD-Kemeny-1999" TOTAL_1="74" TOTAL_2="82" WEIGHT="22.222595059442046"/>
<IV_DATA CI_END="2.1508522123216114" CI_START="0.9144210543708735" EFFECT_SIZE="1.4024209595506814" ESTIMABLE="YES" ESTIMATE="0.3382" LOG_CI_END="0.3326105705091614" LOG_CI_START="-0.03885378294980179" LOG_EFFECT_SIZE="0.1468783937796798" ORDER="2" SE="0.2182" STUDY_ID="STD-Kemeny-2002" TOTAL_1="53" TOTAL_2="56" WEIGHT="22.693551510921314"/>
<IV_DATA CI_END="1.6923430441747036" CI_START="0.8794012635379871" EFFECT_SIZE="1.219937953908705" ESTIMABLE="YES" ESTIMATE="0.1988" LOG_CI_END="0.22848840071924742" LOG_CI_START="-0.05581291471451445" LOG_EFFECT_SIZE="0.08633774300236643" ORDER="3" SE="0.167" STUDY_ID="STD-Lorenz-1998" TOTAL_1="113" TOTAL_2="113" WEIGHT="38.74173069808301"/>
<IV_DATA CI_END="0.9344683103941136" CI_START="0.21352049906260534" EFFECT_SIZE="0.44668572844175436" ESTIMABLE="YES" ESTIMATE="-0.8059" LOG_CI_END="-0.029435421791115864" LOG_CI_START="-0.6705604241405453" LOG_EFFECT_SIZE="-0.3499979229658306" ORDER="4" SE="0.3766" STUDY_ID="STD-Lygidakis-1995" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.6181817373071725"/>
<IV_DATA CI_END="2.9323892446288227" CI_START="0.6072482866526846" EFFECT_SIZE="1.3344243495228993" ESTIMABLE="YES" ESTIMATE="0.2885" LOG_CI_END="0.46722161793849576" LOG_CI_START="-0.21663370188031952" LOG_EFFECT_SIZE="0.12529395802908816" ORDER="5" SE="0.4017" STUDY_ID="STD-Rudroff-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="6.695889788778803"/>
<IV_DATA CI_END="3.2959267104036507" CI_START="0.06120738811732071" EFFECT_SIZE="0.44914926847309944" ESTIMABLE="YES" ESTIMATE="-0.8004" LOG_CI_END="0.5179775459798241" LOG_CI_START="-1.2131961526105497" LOG_EFFECT_SIZE="-0.34760930331536277" ORDER="6" SE="1.0169" STUDY_ID="STD-Tono-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="1.0448536533052013"/>
<IV_DATA CI_END="4.159231181248192" CI_START="0.0682942130094201" EFFECT_SIZE="0.5329647457830451" ESTIMABLE="YES" ESTIMATE="-0.6293" LOG_CI_END="0.6190130602904171" LOG_CI_START="-1.1656160952138497" LOG_EFFECT_SIZE="-0.2733015174617164" ORDER="7" SE="1.0483" STUDY_ID="STD-Wagman-1990" TOTAL_1="6" TOTAL_2="5" WEIGHT="0.9831975521624776"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.9995967101242504" CI_END="1.5987023662681015" CI_START="0.982886516962714" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2535322095747294" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.20376761776811703" LOG_CI_START="-0.007496622454714523" LOG_DATA="YES" LOG_EFFECT_SIZE="0.09813549765670125" NO="2" P_CHI2="0.7358331745906624" P_Q="1.0" P_Z="0.06862707750760626" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="200" WEIGHT="100.00000000000001" Z="1.8208669939519913">
<NAME>Sensitivity analysis excluding for quality</NAME>
<GROUP_LABEL_1>Hepatic Artery Chemo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.1508522123216114" CI_START="0.9144210543708735" EFFECT_SIZE="1.4024209595506814" ESTIMABLE="YES" ESTIMATE="0.3382" LOG_CI_END="0.3326105705091614" LOG_CI_START="-0.03885378294980179" LOG_EFFECT_SIZE="0.1468783937796798" ORDER="1" SE="0.2182" STUDY_ID="STD-Kemeny-2002" TOTAL_1="53" TOTAL_2="56" WEIGHT="32.345785022702216"/>
<IV_DATA CI_END="1.6923430441747036" CI_START="0.8794012635379871" EFFECT_SIZE="1.219937953908705" ESTIMABLE="YES" ESTIMATE="0.1988" LOG_CI_END="0.22848840071924742" LOG_CI_START="-0.05581291471451445" LOG_EFFECT_SIZE="0.08633774300236643" ORDER="2" SE="0.167" STUDY_ID="STD-Lorenz-1998" TOTAL_1="113" TOTAL_2="113" WEIGHT="55.21972583112626"/>
<IV_DATA CI_END="2.9323892446288227" CI_START="0.6072482866526846" EFFECT_SIZE="1.3344243495228993" ESTIMABLE="YES" ESTIMATE="0.2885" LOG_CI_END="0.46722161793849576" LOG_CI_START="-0.21663370188031952" LOG_EFFECT_SIZE="0.12529395802908816" ORDER="4" SE="0.4017" STUDY_ID="STD-Rudroff-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="9.54384823985416"/>
<IV_DATA CI_END="3.2959267104036507" CI_START="0.06120738811732071" EFFECT_SIZE="0.44914926847309944" ESTIMABLE="YES" ESTIMATE="-0.8004" LOG_CI_END="0.5179775459798241" LOG_CI_START="-1.2131961526105497" LOG_EFFECT_SIZE="-0.34760930331536277" ORDER="5" SE="1.0169" STUDY_ID="STD-Tono-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="1.489260578439227"/>
<IV_DATA CI_END="4.159231181248192" CI_START="0.0682942130094201" EFFECT_SIZE="0.5329647457830451" ESTIMABLE="YES" ESTIMATE="-0.6293" LOG_CI_END="0.6190130602904171" LOG_CI_START="-1.1656160952138497" LOG_EFFECT_SIZE="-0.2733015174617164" ORDER="6" SE="1.0483" STUDY_ID="STD-Wagman-1990" TOTAL_1="6" TOTAL_2="5" WEIGHT="1.4013803278781478"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.9654935229881024" CI_END="1.6266785514482958" CI_START="0.996429485985542" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="1.273134114256362" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.2113017403217109" LOG_CI_START="-0.0015534294581493904" LOG_DATA="YES" LOG_EFFECT_SIZE="0.10487415543178073" NO="3" P_CHI2="0.8096006823072093" P_Q="1.0" P_Z="0.05343902750070466" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="190" WEIGHT="100.0" Z="1.9313561213282255">
<NAME>Sensitivity analysis excluding confounders</NAME>
<GROUP_LABEL_1>Hepatic Artery Chemo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.1508522123216114" CI_START="0.9144210543708735" EFFECT_SIZE="1.4024209595506814" ESTIMABLE="YES" ESTIMATE="0.3382" LOG_CI_END="0.3326105705091614" LOG_CI_START="-0.03885378294980179" LOG_EFFECT_SIZE="0.1468783937796798" ORDER="1" SE="0.2182" STUDY_ID="STD-Kemeny-2002" TOTAL_1="53" TOTAL_2="56" WEIGHT="32.83478046417219"/>
<IV_DATA CI_END="1.6923430441747036" CI_START="0.8794012635379871" EFFECT_SIZE="1.219937953908705" ESTIMABLE="YES" ESTIMATE="0.1988" LOG_CI_END="0.22848840071924742" LOG_CI_START="-0.05581291471451445" LOG_EFFECT_SIZE="0.08633774300236643" ORDER="2" SE="0.167" STUDY_ID="STD-Lorenz-1998" TOTAL_1="113" TOTAL_2="113" WEIGHT="56.054523755854035"/>
<IV_DATA CI_END="2.9323892446288227" CI_START="0.6072482866526846" EFFECT_SIZE="1.3344243495228993" ESTIMABLE="YES" ESTIMATE="0.2885" LOG_CI_END="0.46722161793849576" LOG_CI_START="-0.21663370188031952" LOG_EFFECT_SIZE="0.12529395802908816" ORDER="3" SE="0.4017" STUDY_ID="STD-Rudroff-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="9.688129736812558"/>
<IV_DATA CI_END="4.159231181248192" CI_START="0.0682942130094201" EFFECT_SIZE="0.5329647457830451" ESTIMABLE="YES" ESTIMATE="-0.6293" LOG_CI_END="0.6190130602904171" LOG_CI_START="-1.1656160952138497" LOG_EFFECT_SIZE="-0.2733015174617164" ORDER="4" SE="1.0483" STUDY_ID="STD-Wagman-1990" TOTAL_1="6" TOTAL_2="5" WEIGHT="1.4225660431612104"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Meta-analysis of Randomized Studies of Hepatic Artery Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer.<BR/>At no point is the divergence of these curves statistically significant. (6 studies) is a sensitivity analysis performed in the absence of one study (see text).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmwAAAHUCAMAAACwOoSSAAADAFBMVEX////39/dzc3MICAjOzs7v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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>